Quality Assistance held the first meeting of its Scientific Advisory Board
25th November 2025
On 25 November 2025, we held the very first meeting of our Scientific Advisory Board (SAB). This milestone strengthens the analytical and scientific support we provide to our client throughout their drug development programmes.
For our partners and clients, the SAB adds strategic insights to our services, ensuring our analytical solutions offering stay aligned with evolving modalities, technologies and regulatory standards. It reinforces our ability to produce data and develop methods that are not only robust and compliant, but also fully adapted to the scientific challenges our clients face.
Bringing together renowned leaders from the (bio)pharmaceutical industry and academia alongside our internal scientific leaders, the SAB combines external perspective with internal expertise to sharpen the relevance and efficiency of our services. The role of the SAB is to:
Identify and prioritise emerging therapeutic modalities, ensuring that we develop the analytical capabilities our clients will need tomorrow.
Guide our investments in advanced analytical techniques and technologies so we can anticipate scientific and regulatory shifts before they impact development timelines.
Strengthen our forward-looking approach, enabling us to provide proactive guidance
This structured collaboration enhances our ability to deliver faster more reliable and analytical solutions, supporting our mission to accelerate access to tomorrow’s life-changing therapies through analytical excellence and trusted partnership.